

Award Number: W81XWH-12-1-0212

TITLE: Wnt/beta-Catenin, Foxa2, and CXCR4 Axis Controls Prostate Cancer Progression

PRINCIPAL INVESTIGATOR: Xiuping Yu

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center  
Grand Rapids, MI 49503

REPORT DATE: July 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> July 2015		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 1Jul2014 - 30Jun2015	
<b>4. TITLE AND SUBTITLE</b>  Wnt/beta-Catenin, Foxa2, and CXCR4 axis controls prostate cancer progression				<b>5a. CONTRACT NUMBER</b> W81XWH-12-1-0212	
				<b>5b. GRANT NUMBER</b> PC111074	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Xiuping Yu, Ph.D.  E-Mail: xyu@lsuhsc.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Vanderbilt University Medical Center Grand Rapids, MI 49503				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Wnt/beta-Catenin signaling and associated target genes are implicated in the establishment of bone metastasis and in the development of castration resistant prostate cancer. Our previous studies have shown that Foxa2 is a Wnt/beta-catenin target gene in prostates. Our preliminary study suggests a Wnt-Foxa2-CXCR4 axis that is involved in PCa bone metastasis, and activation of this axis provides survival mechanisms for PCa cells following androgen deprivation. The hypothesis is that the Wnt/beta-catenin activation of Foxa2 and CXCR4 promotes progression to CRPCa and facilitates bone colonization by PCa cells, and that targeting this axis will provide a novel treatment for PCa bone metastasis and relapse after androgen ablation.  Last October 1st, I moved from Vanderbilt to LSU Health Sciences Center, Shreveport, LA. This award is undergoing an institutional transfer. Since funds have been tied up during the transition, I have not been able to conduct any research related to this project since I moved to LSUHSC.					
<b>15. SUBJECT TERMS</b> Wnt beta-Catenin, Foxa2, CXCR4, prostate cancer, metastasis, castrate resistant					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  UU	<b>18. NUMBER OF PAGES</b>  4	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b> U	<b>b. ABSTRACT</b> U	<b>c. THIS PAGE</b> U			<b>19b. TELEPHONE NUMBER</b> (include area code)

## Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusion.....	4
References.....	4
Appendices.....	4

**Introduction**

Due to the transitional state of the award most of last year, we conducted few experiments.

**Body**

We have optimized methods for invasion assays and stroma/epithelia co-culture. These methods will be used in the future research related to this project.

**key research accomplishments**

We have optimized methods for invasion assays and stroma/epithelia co-culture.

**Reportable outcomes**

none

**Conclusions**

We are ready to continue the research related to this project.

**References**

None

**Appendice**

None